



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Marc Feldmann, Ravinder N. Maini and
Richard O. Williams

Serial No. : 10/762,096

Filed : January 20, 2004

For : TREATMENT OF TUMOR NECROSIS FACTOR-MEDIATED
DISEASES

1185 Avenue of the Americas
New York, New York 10036
February 17, 2005

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants would like to direct the Examiner's attention to the following documents which are listed on the attached Form PTO-1449 (**EXHIBIT A**). Copies of the documents listed below as items 7 and 8 are attached hereto as **EXHIBITS 1** and **2**:

1. U.S. Patent No. 5,741,488, issued April 21, 1998
(Feldmann, et al.);
2. U.S. Patent No. 6,270,766, issued August 7, 2001
(Feldmann, et al.);
3. U.S. Patent No. 6,770,279, issued August 3, 2004
(Feldmann, et al.);

Applicants : Marc Feldmann et al.
Serial No. : 10/762,096
Filed : January 20, 2004
Page 2

4. U.S. Patent Application Publication No. 2002/0010180 A1, published January 24, 2002;
5. U.S. Patent Application Publication No. 2002/0068057 A1, published June 6, 2002;
6. U.S. Patent Application Publication No. US 2002/0136723 A1, published September 26, 2002;
7. St. Clair, E. W., et al., "Combination of Infliximab and Methotrexate Therapy for Early Rheumatoid Arthritis", Arthritis & Rheumatism, 50(11);3432-3443 (2004) (**EXHIBIT 1**); and
8. Klareskog, L., et al., "Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial", The Lancet, 363:675-681 (2004) (**EXHIBIT 2**).

Because the above-identified application was filed after June 30, 2003, copies of the U.S. Patents and Patent Application Publications listed as items 1-6 are not required and are not provided.

If a telephone conference would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorneys invite the Examiner to telephone them at the number provided below.

Applicants : Marc Feldmann et al.
Serial No. : 10/762,096
Filed : January 20, 2004
Page 3

No fee is deemed necessary in connection with the filing of this Supplemental Information Disclosure Statement. However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White
Registration No. 28,678
Alan J. Morrison
Registration No. 37,399
Attorneys for Applicant
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Alan J. Morrison
Reg. No. 37,399

2/12/05
Date

Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Application Number	10/762,096
	Filing Date	January 20, 2004
	First Named Inventor	Marc Feldmann
	Art Unit	
	Examiner Name	
	Attorney Docket No.	1455/65019-CA-Z- PCT-US/JPW/AJM/CY

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		US-5741488	04-21-1998	Feldmann, et al.
		US-6270766	08-07-2001	Feldmann, et al.
		US-6770279	08-03-2004	Feldmann, et al.
		US-20020010180-A1	01-24-2002	Feldmann, et al.
		US-20020068057-A1	06-06-2002	Feldmann, et al.
		US-20020136723-A1	09-26-2002	Feldmann, et al.

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ Number-Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T ⁶

EXAMINER
SIGNATURE

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds of Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English Language Translation is attached.

Applicants: Marc Feldmann et al.
 Serial No.: 10/762,096
 Filed: January 20, 2004
 Exhibit A

[illegible]**DATE CONSIDERED**

* **EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a checkmark here if English language Translation is attached.